期刊文献+

s-油酰丙醇胺对人脐静脉内皮细胞黏附分子表达的影响 被引量:3

The effect of s-Oleylpropanolamide on the expression of cell adhesion molecules in human umbilical vein endothelial cells
下载PDF
导出
摘要 目的探讨s-油酰丙醇胺对用肿瘤坏死因子α(TNF—α)诱导的人脐静脉内皮细胞黏附分子(VCAM-1,I-CAM-1,E选择素)表达的影响。方法从新鲜的脐带中分离出人脐静脉内皮细胞,培养至3~9代,用不同浓度的s-油酰丙醇胺(10,50,100μmol/L)孵育12h后,用TNF-α(20ng/mL)孵育8h,采用荧光实时定量PCR和细胞酶联免疫吸附试验分别检测VCAM-1,ICAM-1,E选择素的mRNA及蛋白的表达,同时采用细胞黏附实验检测其对细胞黏附的影响。结果相对于正常的人脐静脉内皮细胞,TNF—α诱导后的人脐静脉内皮细胞黏附分子(VCAM-1,ICAM-1,E-选择素)的表达明显增加。s-油酰丙醇胺可以显著的抑制VCAM-1的表达,并呈现出一定的剂量依赖性,而且对人急性单核细胞性白血病细胞(THP-1)的黏附也有明显的抑制作用,但对ICAM-1,E-选择素的表达却没有影响。结论s-油酰丙醇胺和大多数的PPARα激动剂一样,能够抑制慢性炎症,减少单核细胞的黏附,抑制VCAM-1的表达,而对急性炎症没有作用,如对E-选择素的表达无影响。 Purpose To investigate the effect of s-Oleylpropanolamide on the expression of cell adhesion molecules such as VCAM-1, ICAM-1, E-selectin in human umbilical vein endothelial cells(HUVECs). Meth- ods HUVECs were pretreated with different concentrations of s-Oleylpropanolamide for 12 h and then stimulated with TNF-α for 8 h. Cell Enzyme linked immunsorbendt assay. Real-time PCR and adhesion assay were performe to measure the expression of ahesion molecules in mRNA and protein levels and monocyte binding. Resuits s-Oleoylpropanolamide inhibited monoeyte binding and the expression of VCAM-1,an adhesion molecule relatively specific for monocyte and lymphocyte adhesion and chronic inflammation. However it showed no effect on the expression of E-selectin nor ICAM-1. Conclusion s-Oleoylpropanolamide has the same effect as most of PPARa activitors on inhibiting the development of atherosclerosis.
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2009年第2期99-102,共4页 Chinese Journal of Biochemical Pharmaceutics
基金 厦门市科技计划高校创新项目(3502Z20083007) 厦门大学"活性有机小分子的合成化学与化学生物学"创新团队项目
关键词 s-油酰丙醇胺 过氧化物酶体增殖物激活受体Α 人脐静脉内皮细胞 细胞黏附分子 s-Oleylpropanolamide peroxisome proliferator-activated receptor a human umbilical vein endothelial cells cell adhesion molecules
  • 相关文献

参考文献12

  • 1Zandbergen F, Plutzky J. PPARα in atherosclerosis and inflammation [J]. Biochim Biophys Acta, 2007,177 : 972-982.
  • 2Bouhlel M A, Staels B, Chinetti-Gbaguidi G. Peroxisome proliferatoractivated receptors from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease [ J ]. J Intern Med, 2008,263 : 28-42.
  • 3Marx N, Galina K S, Collins T, et al. PPAR activators inhibit cytokine- induced vascular cell adhesion molecule-1 expression in human endothelial cells[J]. Circulation, 1999,99 : 3125-3131.
  • 4Zapolska-Downa; D, Siennicka A,Kaczmarczyk M,et al. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-kB and PPAR-a[J]. Nutr Biochem, 2004,15 : 220-228.
  • 5Wang Yan, Wang Yah, Yang Qi, et al. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells [ J ]. Atherosclerosis, 2006, 187 : 265- 273.
  • 6Guzman M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-aetirated receptor a (PPAR-a) [ J ]. J Biol Chem, 2004, 279: 27849- 27854.
  • 7Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-a [ J ]. Nature, 2003,425 : 90-93.
  • 8秦文,金鑫,陈彩霞,张锋,徐鹏翔,傅瑾.油酰乙醇胺对人脐静脉内皮细胞血管细胞黏附分子-1表达的影响[J].中国生化药物杂志,2008,29(6):374-377. 被引量:6
  • 9Hagiwara H, Mitsumata M, Ymnane T, et al. Laminar shear stress-Induced GRO mRNA and protein expression in endothelial cells[J]. Circulation, 1998,98 : 2584-2590.
  • 10Abe Y, Sugisaki K, Dannenberg A M. Rabbit vascular endothelial adhe-sion molecules: ELAM-1 is most elevated in acute inflammation, whereas VCAM-1 and ICAM-1 predominate in chronic inflammation [J]. Leukoc Biol, 1996,60 : 692-703.

二级参考文献12

  • 1Marzo V D, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons [ J ]. Nature, 1994,372 : 686-691.
  • 2Stena N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons[ J]. Eur J Pharmacol, 2001,425 : 189- 196.
  • 3Rodriguez F, Fonseca D, Navarro M, et al. An anorexic lipid mediator regulated by feeding[ J]. Nature, 2001,414 : 209-212.
  • 4Guzman M, Lo Verme J, Fu J, ct al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor a(PPAR-α) [ J]. J Biol Chem, 2004,279 : 27849-27854.
  • 5Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α[ J]. Nature, 2003,425 : 90-93.
  • 6Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism [ J ]. Circulation, 1998,98 : 2088-2093.
  • 7Rival Y, Beneteau N, Taillandier T, et al. PPARa and PPAR3 activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM- 1 in EAhy926 endothelial ceils [ J ]. Eur J Pharmacol, 2002, 435 : 143-151.
  • 8Lefebvre P, Chinetti G, Stael B, et al. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis [ J ]. J Clin Invest, 2006, 116:571-579.
  • 9Marx N, Sukhova G K, Collins T, et al. PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human wndothelial cells[J]. Circulation, 1999,99:3125-3131.
  • 10Proulx K, Cota D, Tso P, et al. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity[J]. Am J Physiol Regul Integr Comp Physiol, 2005,20 : 213-217.

共引文献5

同被引文献26

  • 1Kazatchkine M D, Kaveri S V. Immunomodulation of autoimmune and inflammatory, diseases with intravenous immune globulin [ J ]. N Engl J Med,2001,345(10) :747-755.
  • 2Ephrem A, Misra N, Hassan G, et al. Immunomodulation of autoim- mune and inflammatory diseases with intravenous immunoglobulin [ J ]. Clin Exp Med ,2005,5 ( 4 ) : 135-140.
  • 3SibOril S,Elluru S, Graff-Dubois S,et al. Intravenous immunoglob- ulins in autoimmune and inflammatory diseases:a mechanistic per- spective [ J ]. Ann NY Acad Sci ,2007,1110:497-506.
  • 4Negi V S, Elluru S, Siberil S, et al. Intravenous immunoglobulin : an update on the clinical use and mechanisms of action [ J ]. J Clin Immuno1,2007,27 ( 3 ) :233 -245.
  • 5Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins [ J ]. Expert Rev Clin lmmunol, 2010,6(3) :425-434.
  • 6Xu C,Poirier B,Duong Van Huyen J P,et al. Modulation of endo- thelial cell function by normal polyspecific human intravenous im- munoglobulins:a possible mechanism of action in vascular diseases [J]. Am J Pathol,1998,153(4) :1257-1266.
  • 7Makata H, Ichiyama T, Uchi R, et al. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in t,itro:implication for treatment of Kawasaki disease [ J ]. Naunyn Schmiedebergs Arch Pharmacol,2006,373 ( 5 ) :325-332.
  • 8Wu K H,Wu W M,Lu M Y,et al. Inhibitory, effect of pooled hu- man immunoglobulin on cytokine production in peripheral blood mononuclear cells [ J ]. Pediatr Allergy Immunol, 2006,17:60-68.
  • 9Schwarlz-Albiez R, Monteiro R C bodies,intravenous immunoglobu ty, cancer and inilam,nation [ J ] (Suppll) :43-50. Rodriguez M ,et al. Natural anti- n and their role in autoimmuni- Clin Exp lmmunol,2009, 158.
  • 10Nakatani K, Takeshita S, Tsujimoto H, et al. Intravenous immuno- globulin(IVIG) preparations induce apoptosis in TNF-alpha-stimu- lated endothelial cells via a mitochondria-dependent pathway[ J]. Clin Exp Immunol,2002,127 ( 3 ) :445-454.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部